DNA topoisomerase inhibitors block erythropoiesis and delay hemoglobinization in vitro.
To examine the importance of topological constraints on DNA during erythroid development, we measured the effects of camptothecin and teniposide, two tumoricidal agents which are also specific inhibitors of type I and type II topoisomerases respectively, on the formation of hematopoietic colonies by cultured human bone marrow cells. When added to bone marrow culture, each inhibitor alone impairs the formation of early BFU-E-derived colonies, late CFU-E-derived colonies and mixed hematopoietic (CFU-GEMM-derived) colonies by up to 100%. Inhibition of colony formation is directly related to the time of inhibitor addition and the inhibitor concentration tested. Although either inhibitor alone reduces colony formation by 90%, when added together at a submaximal concentration, camptothecin and teniposide exert a synergistic suppressive effect. Furthermore, addition of topoisomerase inhibitors to culture impairs hemoglobinization of colony erythroblasts in a time-dependent fashion. In contrast to the effects of topoisomerase inhibitors, the antiproliferative agent aphidicolin reduces erythroid colony number and size without altering hemoglobinization of colony erythroblasts. Since neither topoisomerase inhibitor alters the morphology of cultured cells, the capacity of cells to exclude trypan blue or the potential to form erythroid colonies through the interval required for the first progenitor cell division, it is unlikely that camptothecin or teniposide are cytotoxic to hematopoietic cells. Human mononuclear cells enriched in bone marrow lymphocytes and nucleated erythroblasts from both human and mouse sources release DNA into the detergent soluble fraction. Release requires functional topoisomerases and is altered by acute exposure to topoisomerase inhibitors. Our results suggest that topoisomerases are critical not only to proliferation but also to differentiation of human marrow erythroid progenitor cells and stem cells in culture.
Dainiak
N
N
Department of Medicine, University of Connecticut, Farmington.
Kreczko
S
S
Hanspal
M
M
Strauss
P R
PR
D016590:Aphidicolin; D002166:Camptothecin / Q000494:pharmacology; D002454:Cell Differentiation; D002455:Cell Division; D004224:Diterpenes / Q000494:pharmacology; D004912:Erythrocytes / Q000166:cytology; D004920:Erythropoiesis / Q000187:drug effects*; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D013713:Teniposide / Q000494:pharmacology; D059004:Topoisomerase I Inhibitors
D004224:Diterpenes; D006454:Hemoglobins; D059004:Topoisomerase I Inhibitors; D016590:Aphidicolin; D013713:Teniposide; D002166:Camptothecin